NASHA BE for Enhancement of the Shape and Fullness of the Female Breast (COBRA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Q-Med AB
ClinicalTrials.gov Identifier:
NCT01308853
First received: February 22, 2011
Last updated: May 31, 2012
Last verified: February 2011
  Purpose

The study evaluates treatment procedure, efficacy and safety of NASHA BE for female breast enhancement.


Condition Intervention Phase
Breast Enhancement
Device: NASHA BE
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: An Open, Multi-center Study Evaluating Treatment Procedure, Efficacy and Safety of NASHA BE for Enhancement of the Shape and Fullness of Teh Female Breast

Further study details as provided by Q-Med AB:

Primary Outcome Measures:
  • The primary objective is to develop an injection technique for placement of the implant posterior to the mammary gland. This will be documented through MRI 1-5 days after the injection and evaluated by the Expert Group 6 weeks after treatment. [ Designated as safety issue: No ]
    Inclusion was made in steps, each step incl. treatment of 2 subjects at each of the 2 sites (1 group). The subjects were followed-up with MRI 1-5 days after the injection. Before the next group of 4 subjects were treated, the Expert Group evaluated the 6-week follow-up results of the previous group. The injection procedure was, if necessary, changed in accordance with specifically pre-defined parameters.The aim of the step-wise inclusion was to refine the injection procedure through implant placement assessment, and to evaluate safety and the esthetic results prior to treating the next group.


Secondary Outcome Measures:
  • Assess the safety at 6 weeks through physical examination, reported adverse events (AEs) and Adverse Experiences reported in a diary during 2 weeks post treatment. [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
  • evaluate esthetic improvement at 6 weeks as judged by the investigator using GEIS [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • evaluate pain experienced during injection under local anesthesia [ Designated as safety issue: No ]
  • assess if inflammatory response is elicited by the implant, using blood sample analysis and body temperature (first 8 treated patients only) [ Designated as safety issue: Yes ]
  • assess if the gel can be detected and delineated from surrounding tissues by mammography as evaluated and commented by the radiologist 12 months after treatment. [ Designated as safety issue: Yes ]
  • assess the safety as documented by physical examination and by AEs reported up to 24 months. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • evaluate, at 12 months, in 4 subjects, any implant damage or displacement caused by compression of the breast in conjunction with mammographic investigation using MRI [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • evaluate the esthetic improvement as judged by an independent evaluator, by the investigator and by the subject using GEIS, up to 24 months. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • evaluate, up to 24 months, the subjects satisfaction with her breast and general appearance using a questionnaire. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: March 2007
Study Completion Date: May 2010
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: NASHA BE
    Device: NASHA BE (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast.
  Eligibility

Ages Eligible for Study:   25 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female between 25 and 50 years of age with small breasts seeking enhancement of the shape and fullness of the breast

Exclusion Criteria:

  • Unreasonable expectations
  • Any medical condition that may interfere with the treatment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01308853

Sponsors and Collaborators
Q-Med AB
Investigators
Principal Investigator: Per Hedén, M.D. Akademikliniken, Stockholm, Sweden
Principal Investigator: Michael Olenius, M.D. Proforma Clinic AB, Stockholm, Sweden
  More Information

No publications provided

Responsible Party: Q-Med AB
ClinicalTrials.gov Identifier: NCT01308853     History of Changes
Other Study ID Numbers: 31GB0607
Study First Received: February 22, 2011
Last Updated: May 31, 2012
Health Authority: Sweden: Medical Products Agency

ClinicalTrials.gov processed this record on April 16, 2014